Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Head & Shoulders, Xolegel form duo

This article was originally published in The Rose Sheet

Executive Summary

Barrier Therapeutics will package a 1.7-oz. bottle of Procter & Gamble's Head & Shoulders anti-dandruff shampoo alongside its seborrheic dermatitis treatment Xolegel in Xolegel Duo, drug company announces May 22. Kit will offer patients a complete treatment regimen for seborrheic dermatitis, an inflammatory skin condition that affects the scalp, face and body. "With an estimated 90% of patients with seborrheic dermatitis believed to have affected areas on the scalp as well as on the face and body, this complete treatment system can help patients effectively manage this irritating and often embarrassing condition," says Al Altomari, CEO of Barrier Therapeutics. The pharmaceutical firm will handle assemblage, distribution, pricing, marketing, promotion and sale of the kits and will receive all proceeds from sales. Xolegel Duo will be available by prescription in June...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS015460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel